ATE181074T1 - Vinylen-azaindolderivate und verfahren zu ihrer herstellung - Google Patents

Vinylen-azaindolderivate und verfahren zu ihrer herstellung

Info

Publication number
ATE181074T1
ATE181074T1 AT94903774T AT94903774T ATE181074T1 AT E181074 T1 ATE181074 T1 AT E181074T1 AT 94903774 T AT94903774 T AT 94903774T AT 94903774 T AT94903774 T AT 94903774T AT E181074 T1 ATE181074 T1 AT E181074T1
Authority
AT
Austria
Prior art keywords
vinylene
production
azaindol
derivatives
azaindol derivatives
Prior art date
Application number
AT94903774T
Other languages
English (en)
Inventor
Franco Buzetti
Angelo Crugnola
Dario Ballinari
Felicita Greco
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Application granted granted Critical
Publication of ATE181074T1 publication Critical patent/ATE181074T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Photoreceptors In Electrophotography (AREA)
AT94903774T 1992-12-23 1993-12-15 Vinylen-azaindolderivate und verfahren zu ihrer herstellung ATE181074T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929226855A GB9226855D0 (en) 1992-12-23 1992-12-23 Vinylene-azaindole derivatives and process for their preparation

Publications (1)

Publication Number Publication Date
ATE181074T1 true ATE181074T1 (de) 1999-06-15

Family

ID=10727139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903774T ATE181074T1 (de) 1992-12-23 1993-12-15 Vinylen-azaindolderivate und verfahren zu ihrer herstellung

Country Status (24)

Country Link
US (1) US5397787A (de)
EP (1) EP0626963B1 (de)
JP (1) JP3507497B2 (de)
KR (1) KR950700296A (de)
CN (1) CN1093707A (de)
AT (1) ATE181074T1 (de)
AU (1) AU670488B2 (de)
CA (1) CA2126228A1 (de)
DE (1) DE69325262T2 (de)
DK (1) DK0626963T3 (de)
ES (1) ES2134926T3 (de)
FI (1) FI943838A0 (de)
GB (1) GB9226855D0 (de)
GR (1) GR3030941T3 (de)
HU (1) HUT67431A (de)
IL (1) IL108087A (de)
MX (1) MX9400206A (de)
MY (1) MY109695A (de)
NZ (1) NZ259330A (de)
PL (1) PL304894A1 (de)
RU (1) RU94040390A (de)
TW (1) TW296383B (de)
WO (1) WO1994014808A1 (de)
ZA (1) ZA939578B (de)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5587385A (en) * 1991-12-24 1996-12-24 Farmitalia Carlo Erba S.R.L. Arylidene-heterocyclic derivatives and process for their preparation
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
WO1996032391A1 (de) * 1995-04-11 1996-10-17 Lonza Ag Verfahren zur herstellung von azaindolen mit aktiviertem kupferchromit katalysator durch katalytische dehydrocyclisierung von alkyl-pyridylaminen (pyridopyridinen)
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU6112896A (en) * 1995-06-07 1996-12-30 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
WO1996040648A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
US6682921B1 (en) 1996-08-21 2004-01-27 New York University Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
ES2239393T3 (es) * 1997-05-07 2005-09-16 Sugen, Inc. Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa.
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6313158B1 (en) 1997-06-20 2001-11-06 Sugen, Inc. Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US20040067531A1 (en) * 1997-08-20 2004-04-08 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
EP1017384B1 (de) * 1997-09-26 2004-11-10 Zentaris GmbH Azabenzimidazol-verbindungen zur modulation der serin/threonin protein-kinase funktion
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
US5935626A (en) * 1997-11-24 1999-08-10 Moorman Manufacturing Company Weather resistant mineral feeds and methods of making same
EP1049786A2 (de) 1998-01-21 2000-11-08 Sugen, Inc. Menschliche orthologe von wart
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
AU3363599A (en) * 1998-03-26 1999-10-18 Max-Planck Institut Fur Biochemie Heterocyclic families of compounds for the modulation of tyrosine protein kinase
DE69926742T2 (de) 1998-04-14 2006-06-14 Sugen Inc Ste20-verwandte proteinkinasen
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6395734B1 (en) 1998-05-29 2002-05-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1117397A1 (de) 1998-08-31 2001-07-25 Sugen, Inc. Geometrisch verhinderte 2-indolinonderivate als modulatoren der protein kinase aktivität
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
ES2301255T3 (es) 1998-12-17 2008-06-16 F. Hoffmann-La Roche Ag 4,5-pirazinaxindoles como inhibidores de proteinoquinasas.
AU770375B2 (en) 1998-12-17 2004-02-19 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular CDK2
AU760039B2 (en) 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
EP1630559A3 (de) * 1998-12-30 2006-06-07 Sugen, Inc. PYK2 (RAFTK) und Entzündung
JP2002540096A (ja) * 1999-03-24 2002-11-26 スージェン・インコーポレーテッド キナーゼ阻害剤としてのインドリノン化合物
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
DK1165544T3 (da) * 1999-04-06 2003-12-01 Abbott Gmbh & Co Kg Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
JP2003512838A (ja) 1999-10-22 2003-04-08 ファルマシア・アンド・アップジョン・カンパニー ショウジョウバエｇタンパク質結合レセプター、核酸、およびそれに関連する方法。
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
US20020010203A1 (en) 1999-12-22 2002-01-24 Ken Lipson Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
EP1259234B9 (de) * 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie
IL151045A0 (en) 2000-02-07 2003-04-10 Abbott Gmbh & Co Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
ATE297395T1 (de) * 2000-02-28 2005-06-15 Sugen Inc 3-(pyrolyllacton)-2-indolinon verbindungen zur verwendung als kinase-hemmstoffe
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US6765012B2 (en) 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US7005444B2 (en) 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
EP1434774A1 (de) 2001-10-10 2004-07-07 Sugen, Inc. 3-(4-substituierte heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivate als protein-kinase-inhibitoren
WO2003082869A1 (en) * 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
MXPA04009434A (es) * 2002-04-03 2005-01-25 Allergan Inc (3z)-3- (3 -hidroisobenzofuran- 1-iliden) -1, 3-dihidro- 2h-indol -2-onas como inhibidores de cinasa.
US7700571B2 (en) 2002-06-05 2010-04-20 Genentech, Inc. Compositions and methods for liver growth and liver protection
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
ES2294344T3 (es) 2002-08-02 2008-04-01 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit.
US6699863B1 (en) 2002-11-27 2004-03-02 Allergan, Inc. Kinase inhibitors for the treatment of disease
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
ES2401330T3 (es) 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
JP2007501229A (ja) 2003-08-06 2007-01-25 スゲン，インコーポレイティド 強力なプロテインキナーゼ阻害剤としての幾何学的に束縛された３−シクロペンチリデン−１，３−ジヒドロインドール−２−オン類
CN1898240B (zh) * 2003-10-15 2011-08-03 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
CN1950347B (zh) 2003-10-23 2012-04-04 Ab科学公司 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
BRPI0509576A (pt) 2004-04-02 2007-05-29 Osi Pharm Inc composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
US7915443B2 (en) 2006-11-16 2011-03-29 Allergan, Inc. Sulfoximines as kinase inhibitors
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2005113561A1 (en) * 2004-05-20 2005-12-01 Sugen, Inc. Cyclicsulfonate pyrrole indolinones as kinase inhibitors
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
AU2005265017A1 (en) * 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US20080242704A1 (en) 2005-04-04 2008-10-02 Ab Science Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors
MX2007014377A (es) * 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
CN100519524C (zh) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007076320A2 (en) * 2005-12-22 2007-07-05 Smithkline Beecham Corporation Compounds
US8338415B2 (en) 2006-01-24 2012-12-25 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
MX2009010284A (es) * 2007-03-28 2010-01-29 Pharmacyclics Inc Inhibidores de la tirosina-cinasa de bruton.
US8663915B2 (en) 2007-04-13 2014-03-04 Agency For Science, Technology And Research Methods of controlling tumorigenesis and diagnosing the risk thereof
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
EP2170830B1 (de) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZOSULFONAMID-VERBINDUNGEN ALS Raf-KINASE-MODULATOREN
US8969313B2 (en) 2007-11-02 2015-03-03 Agency For Science, Technology And Research Methods and compounds for preventing and treating a tumour
WO2009091939A1 (en) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
US20100101977A1 (en) * 2008-06-05 2010-04-29 United Comb & Novelty Corporation Stackable Packaging For Lipped Containers
MX2011000661A (es) * 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
CA2752826A1 (en) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2011028995A1 (en) 2009-09-03 2011-03-10 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
BR112012012156A2 (pt) 2009-11-06 2015-09-08 Plexxikon Inc compostos e métodos para modulação de cinase, e indicações para esta
EP2558099A4 (de) * 2009-11-16 2013-07-17 Univ California San Francisco Kinase-inhibitoren
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
IL300955A (en) 2010-06-03 2023-04-01 Pharmacyclics Llc (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
TR201816421T4 (tr) 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
UA114421C2 (uk) 2012-06-04 2017-06-12 Фармасайклікс Ллс Кристалічна форма інгібітору тирозинкінази брутона
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
EP2890706A1 (de) 2012-08-31 2015-07-08 Westfälische Wilhelms-Universität Münster Verfahren und peptide zur vorbeugung und behandlung von mit bcr-abl und c-abl assoziierten krankheiten
MX2015006168A (es) 2012-11-15 2015-08-10 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas.
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
TWI649081B (zh) 2013-08-02 2019-02-01 製藥公司 治療固態腫瘤之方法
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
MA38961A1 (fr) 2013-09-30 2018-05-31 Pharmacyclics Llc Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
BR112017002231A2 (pt) 2014-08-07 2018-07-17 Pharmacyclics Llc novas formulações de um inibidor de tirosina cinase de bruton
SG11201707122QA (en) 2015-03-03 2017-09-28 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
EP3795609B1 (de) 2015-07-01 2024-04-03 California Institute of Technology Kationische schleimsäurepolymerbasierte abgabesysteme
CN110944634A (zh) 2017-06-30 2020-03-31 加利福尼亚大学董事会 用于调节毛发生长的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009598A1 (en) * 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
GB9000939D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa Improvement in the total synthesis of erbstatin analogs
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.

Also Published As

Publication number Publication date
RU94040390A (ru) 1997-05-27
HUT67431A (en) 1995-04-28
MY109695A (en) 1997-04-30
ES2134926T3 (es) 1999-10-16
ZA939578B (en) 1994-08-11
NZ259330A (en) 1995-12-21
JP3507497B2 (ja) 2004-03-15
AU670488B2 (en) 1996-07-18
HU9401950D0 (en) 1994-09-28
DE69325262D1 (de) 1999-07-15
KR950700296A (ko) 1995-01-16
EP0626963B1 (de) 1999-06-09
DK0626963T3 (da) 1999-12-13
US5397787A (en) 1995-03-14
JPH07504208A (ja) 1995-05-11
IL108087A (en) 1997-09-30
AU5810594A (en) 1994-07-19
CN1093707A (zh) 1994-10-19
EP0626963A1 (de) 1994-12-07
CA2126228A1 (en) 1994-07-07
FI943838A (fi) 1994-08-19
DE69325262T2 (de) 2000-01-20
PL304894A1 (en) 1995-01-09
MX9400206A (es) 1994-07-29
GB9226855D0 (en) 1993-02-17
GR3030941T3 (en) 1999-11-30
FI943838A0 (fi) 1994-08-19
IL108087A0 (en) 1994-04-12
TW296383B (de) 1997-01-21
WO1994014808A1 (en) 1994-07-07

Similar Documents

Publication Publication Date Title
ATE181074T1 (de) Vinylen-azaindolderivate und verfahren zu ihrer herstellung
DE59807405D1 (de) Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende mittel und verfahren zu ihrer herstellung
ATE130604T1 (de) Neue arylethylaminderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
NO950849D0 (no) Derivater av valproin og 2-valproensyreamider og anvendelse som antikonvulsanter
DE69207429D1 (de) Verfahren zur herstellung von substituierten piperidinen
ATE164578T1 (de) Verzweigte aminothiazole-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen die sie enthalten
ATE325788T1 (de) Kristalle von vitamin d derivaten und verfahren zu ihrer herstellung
ATE80390T1 (de) Barbitursaeure-verbindungen, diese enthaltende photoresists und verfahren zu deren herstellung.
ATE132861T1 (de) Derivate von hexahydroazepine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
ATE66209T1 (de) Dihydropyridinamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE172976T1 (de) 3-aminochroman-spiroderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FI954138A (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
DE69007422D1 (de) 1-(4-Aminophenyl)-2-piperidinopropanon-Derivate, Verfahren zu deren Herstellung und therapeutische Verwendung.
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
ATE111093T1 (de) Verfahren zur herstellung von enantiomeren von 3- aminchromanderivaten.
DE3777464D1 (de) Fluorine enthaltende vitamin-d3-derivate und verfahren zu ihrer herstellung.
ATE124219T1 (de) Von l-glutaminsäure abgeleitete süssungsmittel, verfahren zu ihrer herstellung.
DE68907857D1 (de) Beta-d-phenylthioxyloside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE152710T1 (de) (thia)cycloalkyl(b)indole, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen
ATE23340T1 (de) 3-alkylthio-2-0-carbamoylpropan-1,2-diol-1-0phosphocholine und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee